ResearcherUniversité de MontpellierNo recent work listed

Thibaut Mazard

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5069496996. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2021: 1 paper

Papers 1

Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcino… Last author DOI 10.1002/ijc.33225 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Marc Ychou · 1 shared paper, 2021 · strength 0.11
- Paper Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients… DOI 10.1002/ijc.33225 ↗
Eric Assénat · 1 shared paper, 2021 · strength 0.11
- Paper Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients… DOI 10.1002/ijc.33225 ↗
Fabienne Portales · 1 shared paper, 2021 · strength 0.11
- Paper Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients… DOI 10.1002/ijc.33225 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.